Targeting DNA methylation in the treatment of acute myeloid leukemia
10.3969/j.issn.1000-8179.2017.02.268
- VernacularTitle:DNA甲基化靶向药物在急性髓系白血病中的应用
- Author:
Naibai CHANG
- Keywords:
acute myeloid leukemia;
DNA methylation;
histone lysine methylation;
therapy
- From:
Chinese Journal of Clinical Oncology
2017;44(2):64-67
- CountryChina
- Language:Chinese
-
Abstract:
DNA and histone lysine methylations are the main epigenetic modulatory elements in the development and progression of acute myeloid leukemia. Methylation-targeted therapy includes DNA methyltransferase, methylation modulatory protein, and histone-lysine methylation inhibitors. Approved DNA methyltransferase inhibitor (demethylating agent) includes azacytidine and dicitabine, which have been used as antileukemic drug clinically. IDH1/2 inhibitor also showed effective and well tolerated in leukemic patients in phaseⅡclinical study. EZH2 inhibitor and LSD1 inhibitor have completed in vitro study and entered clinical trial. Targeting DNA and histone lysine methylations is an alternative approach for leukemia treatment.
